We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Testosterone Replacement in Hypogonadal Men With Type 2 Diabetes and/or Metabolic Syndrome (the TIMES2 Study).
- Authors
JONES, T. HUGH; ARVER, STEFAN; BEHRE, HERMANN M.; BUVAT, JACQUES; MEULEMAN, ERIC; MONCADA, IGNACIO; MORALES, ANTONIO MARTIN; VOLTERRANI, MAURIZIO; YELLOWLEES, ANN; HOWELL, JULIAN D.; CHANNER, KEVIN S.
- Abstract
OBJECTIVE--This study evaluated the effects of testosterone replacement therapy (TRT) on insulin resistance, cardiovascular risk factors, and symptoms in hypogonadal men with type 2 diabetes and/or metabolic syndrome (MetS). RESEARCH DESIGN AND METHODS--The efficacy, safety, and tolerability of a novel transdermal 2% testosterone gel was evaluated over 12 months in 220 hypogonadal men with type 2 diabetes and/or MetS in a multicenter, prospective, randomized, double-blind, placebo-controlled study. The primary outcome was mean change from baseline in homeostasis model assessment of insulin resistance (HOMA-IR). Secondary outcomes were measures of body composition, glycemic control, lipids, and sexual function. Efficacy results focused primarily on months 0-6 (phase 1; no changes in medication allowed). Medication changes were allowed in phase 2 (months 6-12). RESULTS--TRT reduced HOMA-IR in the overall population by 15.2% at 6 months (P = 0.0183 and 16.4% at 12 months (P = 0.006). In type 2 diabetic patients, glycemic control was significantly better in the TRT group than the placebo group at month 9 (HbA1c: treatment difference, -0.446%: P = 0.035). Improvements in total and LDL cholesterol, lipoprotein a (Lpa), body composition, libido, and sexual function occurred in selected patient groups. There were no significant differences between groups m the frequencies of adverse events (AEs) or serious AEs. The majority of AEs (>95%) were mild or moderate. CONCLUSIONS--Over a 6-month period, transdermal TRT was associated with beneficial effects on insulin resistance, total and LDL-cholesterol, Lpa, and sexual health in hypogonadal men with type 2 diabetes and/or MetS.
- Subjects
HORMONE therapy; INSULIN resistance; TESTOSTERONE; PEOPLE with diabetes; TYPE 2 diabetes; METABOLIC syndrome; HYPOGONADISM
- Publication
Diabetes Care, 2011, Vol 34, Issue 4, p828
- ISSN
0149-5992
- Publication type
Article
- DOI
10.2337/dc10-1233